Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 102 publications
Oral losartan yields subtherapeutic airway exposure compared to nebulized delivery and fails to improve mucociliary clearance in cystic fibrosis.
Journal: Frontiers in pharmacology
Published: February 09, 2026
Differentiating between BK activation and potentiation by vanzacaftor enantiomers.
Journal: American journal of physiology. Cell physiology
Published: January 12, 2026
Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.
Journal: The Journal of clinical investigation
Published: August 07, 2025
Short-lived reactive components substantially contribute to particulate matter oxidative potential.
Journal: Science advances
Published: March 19, 2025
Therapeutic strategies to reverse cigarette smoke-induced ion channel and mucociliary dysfunction in COPD airway epithelial cells.
Journal: American journal of physiology. Lung cellular and molecular physiology
Published: March 17, 2025
Impact of Hydrophobic, Hydrophilic, and Mucus-Binding Motifs on the Therapeutic Potential of Ceftazidime Analogs for Pulmonary Administration.
Journal: Antibiotics (Basel, Switzerland)
Published: December 26, 2024
Selective amino acid formulation enhances anion secretion and restores function in cystic fibrosis mutations.
Journal: Frontiers in pharmacology
Published: November 04, 2024
The Pulmonary Perspective: Can E-Cigarettes Be Labeled as Safe Smoking Cessation Tools?
Journal: American journal of respiratory and critical care medicine
Published: July 30, 2024
ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 05, 2024
The combination of propylene glycol and vegetable glycerin e-cigarette aerosols induces airway inflammation and mucus hyperconcentration.
Journal: Scientific reports
Published: August 28, 2023
SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 22, 2023
Last Updated: 09/26/2026